Kaempferol-piperine co-amorphous compound and preparation method thereof

Through the preparation of co-amorphous complexes of kaempol and piperine, the problems of poor water solubility and rapid metabolism of kaempol are solved, significantly improving its bioavailability and therapeutic advantages, and providing new ideas for optimizing drug properties.

CN119019357APending Publication Date: 2024-11-26CHANGZHOU UNIV

Patent Information

Application Number
CN202411112353.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The poor water solubility and rapid first-pass metabolism of kaempol lead to low bioavailability of the drug. The existing preparations have problems such as strong hygroscopicity, limited drug loading, difficult particle size to control and poor stability, which limits its drug properties and clinical applications.

Method used

The co-amorphous complex of kaempferol and piperine was prepared by melt quenching or frozen grinding to form a single homogeneous system, which improves the solubility and stability of the drug, and inhibits β-glucuronidase through piperine. II metabolism, enhance oral absorption.

Benefits of technology

It significantly improves the solubility, dissolution and stability of kaempol, realizes the combination of a single homogeneous system, enhances bioavailability and therapeutic advantages, and provides new formulation ideas to optimize the drug properties of kaempol.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019357A_ABST
    Figure CN119019357A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a kaempferol-piperine co-amorphous compound and a preparation method thereof. A co-amorphous compound composed of kaempferol and piperine is prepared according to a certain stoichiometric ratio by adopting a melting shock cooling method or a freezing grinding method. The crystal diffraction characteristics, thermodynamic properties and intermolecular interaction of the kaempferol-piperine co-amorphous compound are verified through PXRD, DSC and FTIR, and it is indicated that a co-amorphous system is formed. The solubility / dissolution rate of the kaempferol-piperine co-amorphous compound is obviously superior to that of a single crystal medicine and a physical mixture thereof, and the kaempferol-piperine co-amorphous compound shows excellent physical stability and has the potential of improving the bioavailability of kaempferol. Meanwhile, the invention provides a new preparation thought for drug combination of other insoluble compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a kaempferol-piperine co-amorphous complex and a preparation method thereof. Background Art

[0002] Kaempferol (KAE) is a natural flavonoid compound extracted from the rhizome of Kaempferia galanga L. of the Zingiberaceae family and the santalum family. Its chemical name is 3,5,7-trihydroxy-2-[4-hydroxyphenyl]-4H-1-benzopyran-4-one, and its chemical structure is as follows:

[0003]

[0004] Kaempferol has a wide range of therapeutic properties such as antioxidant, anti-inflammatory and anti-cancer and has been used to treat liver damage, diabetes, cancer, stroke and other diseases. As an antioxidant, kaempferol counteracts the production of superoxide ions and reduces the formation of reactive oxygen and nitrogen species. It also scavenges hydroxyl radicals, peroxynitrite and hydroxyl radicals generated by Fenton. In addition, kaempferol inhibits the activity of xanthine oxidase and enhances the activities of catalase, heme oxygenase-1 and superoxide dismutase. Kaempferol also exerts anticancer activity through several pathways, such as inhibition of angiogenesis and expression of vascular endothelial growth factor (VEGF), induction of apoptosis, regulation of hypoxia-inducible factor 1-α (HIF-1α), induction of G2 / M cell cycle arrest and caspase-3-dependent apoptosis.

[0005] However, the poor water solubility and rapid first-pass metabolism of kaempferol lead to poor bioavailability of the drug, which seriously restricts its drugability. Studies have shown that kaempferol is easily metabolized by uridine diphosphate glucuronyltransferases (UGTs). The main metabolite catalyzed by rat liver microsomes is kaempferol-7-glucuronide (K-7-G), while small intestinal microsomes mainly produce kaempferol-3-glucuronide (K-3-G). In recent years, a variety of dosage forms have been used to overcome the physical and chemical property defects of KAE, including nanotechnology, liposomes, copolymer micelles, solid dispersions, etc. However, these preparations have the disadvantages of strong hygroscopicity, limited drug loading, difficult to control particle size, poor stability, and difficulty in industrial production, which limits the further application of kaempferol preparations.

[0006] Piperine (PIP) is an alkaloid extracted from various Piper plants, including black pepper (Piper nigrum Linn.) and Piper longum (P. longum). It has a variety of pharmacological effects, including anti-inflammatory, antioxidant, anti-tumor, antidepressant and immunomodulatory. Moreover, piperine can change gastrointestinal membrane dynamics and inhibit enzymes involved in drug metabolism, thereby enhancing oral absorption of drugs, such as regulating drug metabolism by changing the expression of UDP-glucuronyl transferase to improve bioavailability. Piperine has been reported as a highly active β-glucuronidase inhibitor, which is used to enhance the oral absorption of drugs such as quercetin and curcumin. Summary of the invention

[0007] The purpose of the present invention is to provide a kaempferol-piperine co-amorphous complex and a preparation method thereof in view of the deficiencies of the prior art. The present invention aims to improve the water solubility of drugs by using a kaempferol-piperine co-amorphous system and produce potential synergistic therapeutic effects, thereby improving the bioavailability of kaempferol and its clinical application. The method for preparing a co-amorphous complex of kaempferol and piperine provided by the present invention can effectively improve the solubility / dissolution of kaempferol, and the combined use of piperine and kaempferol can potentially inhibit the β-glucuronidase II phase metabolism of kaempferol, so as to enhance the oral absorption and therapeutic advantages of kaempferol, which is of great significance for promoting the practical application of kaempferol.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] The co-amorphous complex of kaempferol-piperine is prepared from kaempferol and piperine in a molar ratio of 1:(0.5-4).

[0010] Preferably, according to the molar ratio, kaempferol:piperine=1:(0.5-2); most preferably, according to the molar ratio, kaempferol:piperine=1:2.

[0011] The kaempferol-piperine co-amorphous complex is prepared by a melt quenching method or a freeze grinding method, and the kaempferol-piperine co-amorphous complex is obtained after vacuum drying.

[0012] The method of preparing the kaempferol-piperine co-amorphous complex by a melt quenching method comprises the following steps:

[0013] (1) Weigh kaempferol and piperine in an appropriate molar ratio and mix them evenly to prepare kaempferol-piperine physical mixtures of different proportions.

[0014] (2) Pour the kaempferol-piperine physical mixture in step (1) into an aluminum foil weighing dish and place it in an oil bath at a melting temperature of 130 to 170° C. for 3 to 15 minutes until it is completely melted.

[0015] Preferably, the melting temperature is 160°C and the melting time is 5 minutes.

[0016] (3) After the kaempferol-piperine physical mixture in step (2) is completely melted, it is immediately cooled in liquid nitrogen at -196°C, and then dried at room temperature to obtain a kaempferol-piperine co-amorphous solid, and the kaempferol-piperine co-amorphous solid is ground to obtain kaempferol-piperine co-amorphous powders of different proportions.

[0017] The present invention is further configured as follows: in step (3), the kaempferol-piperine co-amorphous solid is ground, and the ground kaempferol-piperine co-amorphous powder is sieved, and the sieve size is 80 meshes.

[0018] The method of preparing the kaempferol-piperine co-amorphous complex by freeze grinding comprises the following steps:

[0019] (1) Kaempferol-piperine are mixed in a certain molar ratio to prepare a physical mixture of kaempferol-piperine in different proportions.

[0020] (2) placing the kaempferol-piperine physical mixture in step (1) on a freezer grinder for freeze grinding.

[0021] The cryogenic grinding is placed in a liquid nitrogen environment and mechanically ground at a frequency of 5 to 20 Hz for a grinding time of 15 to 60 minutes.

[0022] Preferably, the freezing grinding frequency is 10 Hz and the grinding time is 45 min.

[0023] The kaempferol-piperine co-amorphous complex prepared by the method of the present invention is analyzed by powder X-ray diffraction, and the spectrum has no sharp diffraction peak.

[0024] The co-amorphous complex of kaempferol and piperine was analyzed by differential scanning calorimetry, and the spectrum showed only one glass transition temperature (T g : 37.8°C) and the melting peak of the drug disappeared.

[0025] The Fourier transform infrared spectrum of the co-amorphous complex of kaempferol-piperine showed the peaks at 3393.69, 3023.06, 2935.44, 2854.84, 1654.74, 1631.73, 1502.05, 1489.52, 1445.60, 1367.73, 1319.58, 1252.63, 1168.48, 1135.54, 1119.72, 1086.21, 1038.06, 994.78, 929.05, 880.89, 842.18, 800.00, 722.88, 705.79, 634.13, 608.98, 568.28, 512.75, and 418.10 cm -1 There is an absorption peak.

[0026] Beneficial effects of the present invention:

[0027] The kaempferol-piperine co-amorphous complex of the present invention can significantly improve the solubility, dissolution rate and stability of kaempferol, and realize the combined medication of a single homogeneous system.

[0028] The kaempferol-piperine co-amorphous complex of the present invention is analyzed by powder X-ray diffraction technology to analyze the crystal diffraction characteristics of the co-amorphous complex, and a wide diffraction halo is shown on the PXRD spectrum, and it is preliminarily judged that kaempferol and piperine exist in an amorphous form. The thermodynamic properties of the co-amorphous are analyzed by differential thermal scanning technology, and there is only one glass transition temperature on the DSC spectrum and the crystal melting point peak disappears, indicating that a single kaempferol-piperine co-amorphous complex is formed. The interaction between kaempferol and piperine molecules is analyzed by Fourier transform infrared spectroscopy, and the FTIR spectrum shows that the kaempferol-piperine co-amorphous complex has intermolecular hydrogen bond interaction.

[0029] The kaempferol-piperine co-amorphous complex of the present invention is evaluated by apparent solubility and in vitro dissolution test, which shows that the solubility and dissolution rate of the kaempferol-piperine co-amorphous complex are significantly improved compared with the crystalline raw material drug, thus solving the poor solubility defect of kaempferol.

[0030] The present invention prepares poorly soluble kaempferol and the glucuronidase inhibitor piperine into a co-amorphous complex by a melt quenching method or a freeze grinding method, thereby improving the physical and chemical property defects of kaempferol (such as solubility, dissolution, stability, etc.), and providing a new formulation idea for optimizing the drugability of kaempferol. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is the powder X-ray diffraction pattern of kaempferol crystals;

[0032] Figure 2 is the powder X-ray diffraction pattern of piperine crystals;

[0033] Figure 3 is a powder X-ray diffraction pattern of the physical mixture of kaempferol and piperine crystals prepared in Example 1;

[0034] Figure 4 is a powder X-ray diffraction pattern of the kaempferol-piperine co-amorphous complex prepared in Example 1;

[0035] Figure 5 This is the DSC graph of kaempferol crystals;

[0036] Figure 6 is the DSC graph of piperine crystals;

[0037] Figure 7 is a DSC graph of the physical mixture of kaempferol and piperine crystals prepared in Example 1;

[0038] Figure 8 is a DSC graph of the kaempferol-piperine co-amorphous complex prepared in Example 1;

[0039] Fig. 9 This is the infrared spectrum of kaempferol;

[0040] Fig.10 This is the infrared spectrum of piperine crystals;

[0041] Fig.11 is an infrared spectrum of the physical mixture of kaempferol and piperine crystals prepared in Example 1;

[0042] Fig.12 is an infrared spectrum of the kaempferol-piperine co-amorphous complex prepared in Example 1;

[0043] Fig.13 is a comparison chart of non-sink dissolution of kaempferol, the physical mixture of kaempferol and piperine crystals prepared in Example 1, and the kaempferol-piperine co-amorphous complex prepared in Example 1 in a pH 6.8 phosphate buffer solution;

[0044] Fig.14 This is a comparison chart of the stability of amorphous kaempferol at 25°C and 40°C;

[0045] Fig.15 This is a comparison chart of the stability of amorphous piperine at 25°C and 40°C;

[0046] Fig.16 This is a stability comparison chart of the kaempferol-piperine co-amorphous complex prepared in Example 1 at 25° C. and 40° C. at different time points. DETAILED DESCRIPTION

[0047] The present invention will be further described below in conjunction with the embodiments.

[0048] Example 1

[0049] 334 mg of kaempferol and 666 mg of piperine were weighed and placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in an aluminum foil weighing dish and floated in a 160°C electric constant temperature oil bath for heating for 5 min. After it was completely melted, it was taken out and immediately placed in liquid nitrogen (-196°C) for rapid cooling. The product was placed in a vacuum drying oven and dried at room temperature for 24 h. The obtained solid product was ground and passed through an 80 mesh sieve. The sieved powder was stored in a solution containing anhydrous CaCl 2 and color-changing silica gel in a desiccator.

[0050] Example 2

[0051] 501 mg of kaempferol and 499 mg of piperine were weighed and placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in an aluminum foil weighing dish and floated in a 160°C electric constant temperature oil bath for heating for 5 min. After it was completely melted, it was taken out and immediately placed in liquid nitrogen (-196°C) for rapid cooling. The product was placed in a vacuum drying oven and dried at room temperature for 24 h. The obtained solid product was ground and passed through an 80 mesh sieve. The sieved powder was stored in a solution containing anhydrous CaCl 2 and color-changing silica gel in a desiccator.

[0052] Example 3

[0053] 667 mg of kaempferol and 333 mg of piperine were weighed and placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in an aluminum foil weighing dish and floated in a 160°C electric constant temperature oil bath for heating for 5 min. After it was completely melted, it was taken out and immediately placed in liquid nitrogen (-196°C) for rapid cooling. The product was placed in a vacuum drying oven and dried at room temperature for 24 h. The obtained solid product was ground and sieved through an 80-mesh sieve. The sieved powder was stored in a solution containing anhydrous CaCl 2 and color-changing silica gel in a desiccator.

[0054] Example 4

[0055] 334 mg of kaempferol and 666 mg of piperine were weighed and placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in an aluminum foil weighing dish and floated in a 150°C electric constant temperature oil bath for heating for 5 min. After it was completely melted, it was taken out and immediately placed in liquid nitrogen (-196°C) for rapid cooling. The product was placed in a vacuum drying oven and dried at room temperature for 24 h. The obtained solid product was ground and sieved through an 80 mesh sieve. The sieved powder was stored in a solution containing anhydrous CaCl 2 and color-changing silica gel in a desiccator.

[0056] Example 5

[0057] About 334 mg of kaempferol and 666 mg of piperine were weighed and placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in an aluminum foil weighing dish and floated in a 170°C electric constant temperature oil bath for heating for 5 min. After it was completely melted, it was taken out and immediately placed in liquid nitrogen (-196°C) for rapid cooling. The product was placed in a vacuum drying oven and dried at room temperature for 24 h. The obtained solid product was ground and passed through an 80 mesh sieve. The sieved powder was stored in a solution containing anhydrous CaCl 2 and color-changing silica gel in a desiccator.

[0058] Example 6

[0059] 334 mg of kaempferol and 666 mg of piperine were weighed separately, placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in a cryo-grinder filled with liquid nitrogen at a frequency of 10 Hz for 15 cycles, each cycle time was 3 min, and then cooled for 1 min. The ground sample was placed in a vacuum drying oven and dried for 24 h to obtain a kaempferol-piperine co-amorphous complex.

[0060] Example 7

[0061] 501 mg of kaempferol and 499 mg of piperine were weighed respectively, placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in a cryo-grinder filled with liquid nitrogen at a frequency of 10 Hz for 15 cycles, each cycle time was 3 min, and then cooled for 1 min. The ground sample was placed in a vacuum drying oven and dried for 24 h to obtain a kaempferol-piperine co-amorphous complex.

[0062] Example 8

[0063] 667 mg of kaempferol and 333 mg of piperine were weighed separately, placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in a cryo-grinder filled with liquid nitrogen at a frequency of 10 Hz for 15 cycles, each cycle time was 3 min, and then cooled for 1 min. The ground sample was placed in a vacuum drying oven and dried for 24 h to obtain a kaempferol-piperine co-amorphous complex.

[0064] Example 9

[0065] 334 mg of kaempferol and 666 mg of piperine were weighed separately, placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in a cryo-grinder filled with liquid nitrogen at a frequency of 20 Hz for 15 cycles, each cycle time was 3 min, and then cooled for 1 min. The ground sample was placed in a vacuum drying oven and dried for 24 h to obtain a kaempferol-piperine co-amorphous complex.

[0066] Example 10

[0067] 334 mg of kaempferol and 666 mg of piperine were weighed respectively, placed in a 10 mL centrifuge tube, and vortexed for 10 min using a vortexer to obtain a kaempferol-piperine co-amorphous physical mixture. The kaempferol-piperine co-amorphous physical mixture was placed in a cryo-grinder filled with liquid nitrogen at a frequency of 5 Hz for 15 cycles, each cycle time was 3 min, and then cooled for 1 min. The ground sample was placed in a vacuum drying oven and dried for 24 h to obtain a kaempferol-piperine co-amorphous complex.

[0068] Test Example 1: The kaempferol-piperine co-amorphous complex in Example 1 was characterized as follows:

[0069] 1. Powder X-ray Diffraction

[0070] Instrument: SmartLab9 X-ray diffractometer (Rigaku, Japan)

[0071] Target: Cu-Kα radiation

[0072] wavelength:

[0073] Tube voltage: 40KV

[0074] Tube current: 40mA

[0075] Step size: 0.02°

[0076] Scanning speed: 4° / min

[0077] Scanning range: 2θ, 5-40°

[0078] The kaempferol crystalline bulk drug, piperine crystalline bulk drug, kaempferol-piperine physical mixture, and kaempferol-piperine co-amorphous complex were detected respectively. The corresponding PXRD patterns are as follows: Figure 1 to Figure 4 shown.

[0079] like Figure 4 As shown, the powder X-ray diffraction pattern of the kaempferol-piperine co-amorphous complex in Example 1 shows that the crystal diffraction peak disappears at 5-40°, presenting a diffuse broad diffraction halo, indicating that kaempferol and piperine coexist in an amorphous state.

[0080] 2. Differential Scanning Calorimetry

[0081] Instrument: HITACHIDSC 7020 differential scanning calorimeter (Hitachi Profile, Japan)

[0082] Range: 25-300℃

[0083] Heating rate: 10℃ / min

[0084] The kaempferol crystalline API, piperine crystalline API, kaempferol-piperine physical mixture, and kaempferol-piperine co-amorphous complex were detected respectively. The corresponding DSC spectra are shown in FIG. Figures 5 to 8 shown.

[0085] like Figure 8 As shown, in the DSC spectrum of the kaempferol-piperine amorphous composite in Example 1, the endothermic melting peak of the kaempferol crystals disappeared, and there was a single glass transition temperature of 37.8°C.

[0086] 3. Fourier transform infrared spectroscopy

[0087] Instrument: Thermo Scientific Nicolet iS50 Fourier transform infrared spectrometer (Thermo Fisher Scientific, America)

[0088] Range: 4000-400cm -1

[0089] Scan times: 64 times

[0090] The kaempferol crystalline bulk drug, piperine crystalline bulk drug, kaempferol-piperine physical mixture, and kaempferol-piperine co-amorphous complex were detected respectively. The corresponding FTIR spectra are as follows Figures 9 to 12 shown.

[0091] like Fig.12 As shown, the FTIR spectrum wave number (cm -1 ) are: 3393.69, 3023.06, 2935.44, 2854.84, 1654.74, 1631.73, 1502.05, 1489.52, 1445.60, 1367.73, 1319.58, 1252.63, 1168.48, 1135.54, 1119.72, 1086.21, 1038.06, 994.78, 929.05, 880.89, 842.18, 800.00, 722.88, 705.79, 634.13, 608.98, 568.28, 512.75 and 418.10 cm -1 .

[0092] Test Example 2: The solubility test of the kaempferol-piperine co-amorphous complex in Examples 1, 3, 5, and 9 is as follows:

[0093] Excess kaempferol crystals, piperine crystals, kaempferol-piperine physical mixture, and kaempferol-piperine co-amorphous complex were weighed separately and placed in EP tubes. 5 mL of phosphate buffer solution (pH 6.8) was added and the tubes were shaken at 37 °C constant temperature shaker for 24 h. The supernatant was filtered through a 0.45 μm microporous filter membrane and diluted by half with methanol. The filtrate was taken for HPLC analysis. Each sample was measured in triplicate.

[0094] The HPLC conditions were as follows:

[0095] Instrument: Agilent 1260 High Performance Liquid Chromatograph

[0096] Chromatographic column: Ultimate XB-C18 (4.6mm×250mm, 5μm)

[0097] Mobile phase: acetonitrile-0.3% phosphoric acid water = 60:40 (V / V)

[0098] Flow rate: 1.0mL / min

[0099] Detection wavelength: 366nm

[0100] Table 1 Solubility of kaempferol crystals, kaempferol-piperine physical mixture and kaempferol-piperine co-amorphous

[0101]

[0102] It can be seen from Table 1 that the solubility of the kaempferol-piperine co-amorphous complex in Example 1 is 6.9 times higher than that of the kaempferol API in pH 6.8 phosphate buffer solution. The kaempferol-piperine co-amorphous complex in Examples 3, 5, and 9 also exhibit significantly improved solubility.

[0103] Test Example 3: The non-sink dissolution test of the kaempferol-piperine co-amorphous complex of Examples 1, 3, 5, and 9 was performed as follows:

[0104] According to the second method of 0931 of the fourth general rule of the 2020 edition of the Chinese Pharmacopoeia, the slurry method was used for non-sink dissolution evaluation. At 37°C ± 0.5°C, kaempferol crystals, kaempferol-piperine physical mixture (molar ratio 1:2), and kaempferol-piperine co-amorphous complex (molar ratio 1:2) were added to 200mL phosphate buffer solution (pH 6.8) and stirred at 100rpm. 2mL samples were taken in EP tubes at 0.08h, 0.17h, 0.33h, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h and 12h, and isothermal and equal volumes of dissolution medium were added at the same time. The liquid was taken out and filtered through a 0.45μm microporous filter membrane and diluted by methanol. The filtrate was taken for HPLC analysis, and each sample was measured in parallel 3 times.

[0105] like Fig.13 As shown in Table 2, the kaempferol bulk drug and the kaempferol-piperine physical mixture showed similar dissolution curves, with low dissolution concentrations, while the dissolution of the kaempferol-piperine co-amorphous complex in Example 1 was significantly improved (5.8 times that of the bulk drug at 12 h), and the supersaturated dissolution concentration continued to increase without a downward trend. The kaempferol-piperine co-amorphous complex in Examples 3, 5, and 9 also showed significantly improved dissolution concentrations at different time points.

[0106] Table 2 Dissolution concentrations of kaempferol crystals and kaempferol-piperine co-amorphous at different time points (μg / mL)

[0107]

[0108] Test Example 4: A stability test was conducted on the kaempferol-piperine co-amorphous complex in Example 1, as follows:

[0109] In order to comprehensively evaluate the stability of the co-amorphous preparations during storage, amorphous kaempferol, amorphous piperine and kaempferol-piperine co-amorphous complex were placed in a drug stability test chamber at 25°C and 40°C for inspection, and powder X-ray diffraction (PXRD) was used to evaluate the physical stability at different time points.

[0110] like Fig.14 As shown, amorphous kaempferol was stored at 25°C and 40°C for 30 days, and the PXRD diffraction pattern showed crystalline characteristic diffraction peaks. The results showed that amorphous kaempferol had recrystallized within 30 days.

[0111] like Fig.15 As shown, amorphous piperine was stored at 25°C and 40°C for 7 days, and the PXRD diffraction pattern showed characteristic diffraction peaks of crystals. The results showed that amorphous piperine had been recrystallized within 7 days.

[0112] like Fig.16 As shown, the kaempferol-piperine co-amorphous complex in Example 1 was stored at 25° C. and 40° C. for 90 days, and no characteristic diffraction peaks were shown in the PXRD diffraction pattern. The results showed that the kaempferol-piperine co-amorphous complex had a high physical stability.

Claims

1. A kaempferol-piperine co-amorphous complex, characterized in that: The co-amorphous composite is prepared from kaempferol and piperine in a molar ratio of 1:(0.5-4).

2. The kaempferol-piperine co-amorphous complex according to claim 1, characterized in that: The molar ratio of kaempferol to piperine is 1:(0.5-2).

3. A method for preparing the kaempferol-piperine co-amorphous complex according to claim 1, characterized in that: The preparation method comprises the following steps: preparing the kaempferol-piperine co-amorphous composite by using a melting quenching method or a freezing grinding method to treat kaempferol and piperine.

4. The method for preparing the kaempferol-piperine co-amorphous complex according to claim 3, characterized in that: The steps of preparing the kaempferol-piperine co-amorphous complex by melt quenching method are as follows: (1) mixing kaempferol and piperine in a molar ratio to form a kaempferol-piperine physical mixture; (2) pouring the kaempferol-piperine physical mixture in step (1) into an aluminum foil weighing dish and floating it in an oil bath until it is completely melted; (3) After the kaempferol-piperine physical mixture in step (2) is completely melted, it is immediately placed in liquid nitrogen for cooling, then dried, and ground to obtain a kaempferol-piperine co-amorphous solid.

5. The method for preparing the kaempferol-piperine co-amorphous complex according to claim 4, characterized in that: In step (2), the melting temperature is 130 to 170° C. and the melting time is 3 to 15 minutes.

6. The method for preparing the kaempferol-piperine co-amorphous complex according to claim 4, characterized in that: In step (3), the liquid nitrogen cooling temperature is -196°C, the drying is room temperature drying, and the ground amorphous powder is sieved with a sieve size of 80 meshes.

7. The method for preparing the kaempferol-piperine co-amorphous complex according to claim 3, characterized in that: The steps of preparing the kaempferol-piperine co-amorphous complex by freeze grinding are as follows: (1) mixing kaempferol and piperine in a molar ratio to form a kaempferol-piperine physical mixture; (2) placing the kaempferol-piperine physical mixture in step (1) on a freezer grinder for freeze grinding.

8. The method for preparing the kaempferol-piperine co-amorphous complex according to claim 7, characterized in that: The cryogenic grinding is placed in a liquid nitrogen environment and mechanically ground at a frequency of 5 to 20 Hz for a grinding time of 15 to 60 minutes.

Citation Information

Patent Citations

  • Kaempferol and isonicotinamide eutectic compound, preparation method, pharmaceutical composition thereof and application

    CN109988104A

  • Co-crystal of 5-fluorouracil and kaempferol and preparation method thereof

    CN112209887A

  • Quercetin-piperine co-amorphous substance with synergistic anti-oxidation and absorption-promoting effects and preparation method of quercetin-piperine co-amorphous substance

    CN118236510A

Cited By

  • Carbamazepine and disodium glycyrrhizinate co-amorphous compound and preparation method thereof

    CN120241618A